NASDAQ:AKLI Akili (AKLI) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free AKLI Stock Alerts $0.24 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$0.23▼$0.2550-Day Range$0.21▼$0.4752-Week Range$0.19▼$1.67Volume22,715 shsAverage Volume100,676 shsMarket Capitalization$19.14 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Akili alerts: Email Address Akili MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,542.7% Upside$4.00 Price TargetShort InterestHealthy0.15% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.53) to ($0.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.03 out of 5 starsMedical Sector362nd out of 908 stocksSurgical & Medical Instruments Industry45th out of 98 stocks 3.5 Analyst's Opinion Consensus RatingAkili has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAkili has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.15% of the float of Akili has been sold short.Short Interest Ratio / Days to CoverAkili has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Akili has recently decreased by 35.39%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAkili does not currently pay a dividend.Dividend GrowthAkili does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AKLI. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Akili this week, compared to 0 articles on an average week.Search Interest11 people have searched for AKLI on MarketBeat in the last 30 days. This is an increase of 175% compared to the previous 30 days.MarketBeat Follows28 people have added Akili to their MarketBeat watchlist in the last 30 days. This is an increase of 833% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akili insiders have not sold or bought any company stock.Percentage Held by Insiders10.10% of the stock of Akili is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.12% of the stock of Akili is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Akili are expected to grow in the coming year, from ($0.53) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akili is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akili is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkili has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Akili Stock (NASDAQ:AKLI)Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.Read More AKLI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKLI Stock News HeadlinesApril 26, 2024 | americanbankingnews.comShort Interest in Akili, Inc. (NASDAQ:AKLI) Declines By 35.4%March 11, 2024 | bizjournals.comDigital medicine maker Akili slashed executive pay in 2023April 26, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.March 3, 2024 | finance.yahoo.comAkili Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 1, 2024 | markets.businessinsider.comAkili (AKLI) Gets a Buy from TD CowenFebruary 29, 2024 | businesswire.comAkili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 28, 2024 | benzinga.comPreview: Akili's EarningsFebruary 28, 2024 | investing.comAkili's ADHD digital therapy seeks Japan approvalApril 26, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.February 27, 2024 | msn.comCrude Oil Gains 1%; US New Home Sales Increase In JanuaryFebruary 27, 2024 | businesswire.comPureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx ® for Pediatric ADHD Patients in JapanFebruary 26, 2024 | investorplace.comWhy Is Akili (AKLI) Stock Up 110% Today?February 26, 2024 | msn.comWhy Is Prescription Digital Medicine-Focused Akili Stock Trading Over 100% On Monday?February 26, 2024 | seekingalpha.comAkili's ADHD device submitted for Japanese approval, stock rallies 130%February 26, 2024 | finance.yahoo.comAkili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in JapanFebruary 26, 2024 | businesswire.comAkili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx® for Pediatric ADHD Patients in JapanFebruary 21, 2024 | finance.yahoo.comAkili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance UpdatesFebruary 21, 2024 | businesswire.comAkili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance UpdatesJanuary 15, 2024 | finance.yahoo.comAkili, Inc. (AKLI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?January 8, 2024 | bbc.comAkli Tadjer: French writer meets students in school race rowDecember 26, 2023 | cnet.comWhat to Know About EndeavorRX, the Video Game to Treat ADHDDecember 21, 2023 | finance.yahoo.comAkili, Inc. (AKLI) Upgraded to Buy: Here's What You Should KnowDecember 21, 2023 | bizjournals.comThe Petri Dish: ADHD-treating videogame cleared for teens, CRISPR exec resignsDecember 19, 2023 | morningstar.comAkili Inc Ordinary SharesDecember 18, 2023 | finance.yahoo.comEndeavorRxⓇ, World’s First and Only Prescription Video Game Treatment, Secures FDA Label Expansion for Pediatric ADHD Patients Aged 13-17November 15, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Urogen Pharma (URGN) and Akili (AKLI)November 14, 2023 | morningstar.comAkili Inc Ordinary Shares AKLISee More Headlines Receive AKLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akili and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/25/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:AKLI CUSIPN/A CIK1850266 Webwww.akiliinteractive.com Phone650-931-6236FaxN/AEmployees68Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+1,542.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,490,000.00 Net Margins-3,545.47% Pretax Margin-3,542.31% Return on Equity-76.34% Return on Assets-56.48% Debt Debt-to-Equity Ratio0.09 Current Ratio6.02 Quick Ratio6.02 Sales & Book Value Annual Sales$1.68 million Price / Sales11.39 Cash FlowN/A Price / Cash FlowN/A Book Value$0.75 per share Price / Book0.32Miscellaneous Outstanding Shares78,600,000Free Float70,658,000Market Cap$19.14 million OptionableOptionable Beta1.99 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Walter Edward Martucci II (Age 41)Ph.D., Co-Founder & Chairman Comp: $759.1kMr. Matthew Franklin M.B.A. (Age 50)President, CEO & Director Comp: $639.13kDr. Adam Gazzaley M.D. (Age 54)Ph.D., Co-Founder, Chief Science Advisor & Director Comp: $126.45kMs. Jacqueline L. Studer J.D. (Age 65)Chief Legal Officer, General Counsel & Secretary Comp: $559.55kMs. Caty ReidVP of Marketing & CommunicationsDr. Scott H. Kollins Ph.D.Chief Medical OfficerMr. Jonathan David (Age 46)Chief Product Officer More ExecutivesKey CompetitorsSTRATA Skin SciencesNASDAQ:SSKNMeihua International Medical TechnologiesNASDAQ:MHUAGlucoTrackNASDAQ:GCTKPAVmedNASDAQ:PAVMGetaroundNYSE:GETRView All CompetitorsInsiders & InstitutionsStoneX Group Inc.Bought 1,064,432 shares on 2/12/2024Ownership: 1.359%Longitude Cayman Ltd.Sold 55,000 shares on 2/8/2024Ownership: 0.255%Walter Edward Martucci IISold 2,353 sharesTotal: $2,470.65 ($1.05/share)Matthew FranklinSold 1,728 sharesTotal: $1,814.40 ($1.05/share)Jacqueline StuderSold 1,130 sharesTotal: $1,186.50 ($1.05/share)View All Insider TransactionsView All Institutional Transactions AKLI Stock Analysis - Frequently Asked Questions Should I buy or sell Akili stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akili in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AKLI shares. View AKLI analyst ratings or view top-rated stocks. What is Akili's stock price target for 2024? 1 analysts have issued 12-month target prices for Akili's stock. Their AKLI share price targets range from $4.00 to $4.00. On average, they anticipate the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 1,542.7% from the stock's current price. View analysts price targets for AKLI or view top-rated stocks among Wall Street analysts. How have AKLI shares performed in 2024? Akili's stock was trading at $0.4871 on January 1st, 2024. Since then, AKLI stock has decreased by 50.0% and is now trading at $0.2435. View the best growth stocks for 2024 here. Are investors shorting Akili? Akili saw a drop in short interest in April. As of April 15th, there was short interest totaling 79,600 shares, a drop of 35.4% from the March 31st total of 123,200 shares. Based on an average daily volume of 2,330,000 shares, the short-interest ratio is currently 0.0 days. Approximately 0.2% of the company's stock are sold short. View Akili's Short Interest. When is Akili's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our AKLI earnings forecast. How were Akili's earnings last quarter? Akili, Inc. (NASDAQ:AKLI) posted its earnings results on Thursday, February, 29th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.12. The business earned $0.75 million during the quarter, compared to analyst estimates of $1.07 million. Akili had a negative trailing twelve-month return on equity of 76.34% and a negative net margin of 3,545.47%. How do I buy shares of Akili? Shares of AKLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AKLI) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akili, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
